Meningococcal Vaccine
Cost-effectiveness of meningococcal vaccine strategies in U.S. examined
Published in Medical Letter on the CDC and FDA, July 17th, 2005
According to a study from the United States, "The U.S. Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.
"The study was done to evaluate and compare the projected health and economic impact of MCV-4 vaccination of U.S. adolescents, toddlers, and infants. Sensitivity analyses in which key input measures were varied over plausible ranges...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Air Pollution
Cardiorespiratory hospitalizations linked to forest fire smoke exposure - Diarrheal Disease
Developing bacterial vaccines to prevent diarrheal diseases reviewed - Food-Borne Illness
Food service workers' self-reported food preparation practices listed - Myelodysplastic Syndrome
Azacitidine approved for treatment of myelodysplastic syndrome - Acne
Company receives FDA nonapprovable letter for Velac - Acute Bacterial Sinusitis
Single-dose antibiotic Zmax receives FDA approval - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
